Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · IEX Real-Time Price · USD
18.59
+0.83 (4.67%)
At close: Dec 7, 2023, 4:00 PM
19.50
+0.91 (4.90%)
After-hours: Dec 7, 2023, 5:46 PM EST
4.67%
Market Cap 933.93M
Revenue (ttm) 347,000
Net Income (ttm) -216.66M
Shares Out 52.59M
EPS (ttm) -5.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 832,301
Open 17.78
Previous Close 17.76
Day's Range 17.78 - 18.98
52-Week Range 10.93 - 39.00
Beta 1.05
Analysts Strong Buy
Price Target 39.45 (+112.21%)
Earnings Date Nov 13, 2023

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeut... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 86
Stock Exchange NASDAQ
Ticker Symbol VRDN
Full Company Profile

Financial Performance

In 2022, VRDN's revenue was $1.77 million, a decrease of -40.20% compared to the previous year's $2.96 million. Losses were -$129.87 million, 63.5% more than in 2021.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price forecast is $39.45, which is an increase of 112.21% from the latest price.

Price Target
$39.45
(112.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

16 days ago - Business Wire

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

24 days ago - Business Wire

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

4 weeks ago - Business Wire

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

4 weeks ago - Business Wire

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

5 weeks ago - Business Wire

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

6 weeks ago - Business Wire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therap...

2 months ago - Accesswire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian The...

2 months ago - Accesswire

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

2 months ago - Business Wire

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

3 months ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therap...

3 months ago - Accesswire

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

4 months ago - Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class med...

4 months ago - Business Wire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therape...

4 months ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeu...

5 months ago - Accesswire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeu...

5 months ago - Accesswire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridian Therapeu...

5 months ago - Accesswire

Viridian stock falls more than 15% after drug study update

Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease ther...

5 months ago - Market Watch

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

5 months ago - Business Wire

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

6 months ago - Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class med...

6 months ago - Business Wire

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 -

7 months ago - GlobeNewsWire

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

- Partnership to support one of the Company's preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a...

7 months ago - GlobeNewsWire

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for ser...

7 months ago - GlobeNewsWire

UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company's thyroid eye disease program -

8 months ago - GlobeNewsWire